Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00460759 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
A Phase 1 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00460759: Clinical Trial Phase 1 study, sponsored by Johns Hopkins University.
NCT00460759 is a Phase 1 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00460759, a Phase 1 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the pharmacokinetics (how a drug is absorbed, distributed, and eliminated by the body) of moxifloxacin alone versus moxifloxacin given with rifapentine. Researchers believe that understanding how these tuberculosis drugs interact when given together may help to determine the best drug treatment plan for use in future studies. Volunteers will take moxifloxacin daily by mouth for the first part of the study and then moxifloxacin in combination with rifapentine during the second part of the study. Sixteen healthy men and women will be recruited from Johns Hopkins University School of Medicine to volunteer for this study. They will be required to stay in the inpatient unit twice, each time for 84 hours. Study procedures will include having a tube placed in a vein to draw several blood samples over time. Volunteers will participate in the study for a maximum of 48 days, including screening and follow-up visits.
Interventions
- DRUG Moxifloxacin
- DRUG Rifapentine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00460759
The ClinicalTrials.gov registry entry for NCT00460759 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Moxifloxacin is the first listed.
NCT00460759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00460759 about?
NCT00460759 is a clinical study titled "Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine". The purpose of this study is to determine the pharmacokinetics (how a drug is absorbed, distributed, and eliminated by the body) of moxifloxacin alone versus moxifloxacin given with rifapentine. Researchers believe that understanding how these tuberculosis drugs interact when given together may help...
What is the current status of trial NCT00460759?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2007-06. Estimated completion is 2008-08-24.
What interventions are being tested in trial NCT00460759?
The interventions under investigation include: Moxifloxacin (DRUG), Rifapentine (DRUG).
Who is sponsoring clinical trial NCT00460759?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.